GSK Expects FY23 Sales Growth Of 8%-10%; Adj. EPS Growth Of 14%-17%; And Adj. Operating Profit 11%-13%
Portfolio Pulse from Benzinga Newsdesk
GlaxoSmithKline (GSK) has projected its FY23 sales growth to be between 8% and 10%. The company also expects its adjusted EPS growth to be between 14% and 17%, and its adjusted operating profit to grow by 11% to 13%.
July 26, 2023 | 7:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's projected growth in sales, adjusted EPS, and operating profit for FY23 could potentially boost investor confidence and positively impact its stock price in the short term.
GSK's projected growth rates for FY23 are quite robust. This indicates that the company is expecting strong performance in the future, which could make the stock more attractive to investors. This increased demand could potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100